drugset / Trial / NCT02661100
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
NaSingle-groupOpen-labelTreatment
Summary
This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer drug. CDX-1401 is a tumor specific antigen and Poly-ICL is a Toll-like receptor agonist tumor specific antigens which when combined with Pembrolizumab may increase the tumor response to this drug.
Timeline
- Start
- 2017-01
- Primary completion
- 2018-07
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg/kg | Intravenous |
| Subject | RASDEGAFUSP ALFA | Vaccine | 1 mg | Subcutaneous |
| Background | Hiltonol | Other / unclassified | 2 mg | Subcutaneous |